In a striking advancement in the field of psychiatric research, scientists have unveiled compelling evidence suggesting that the way N-methyl-D-aspartate (NMDA) receptor antagonists influence negative affective biases in male rodents could dramatically enhance our ability to predict the clinical efficacy of therapeutic agents for major depressive disorder (MDD). This breakthrough emerges from an exhaustive preclinical study that delves deep into the nuanced neuropharmacological mechanisms underpinning depression and its treatment, potentially revolutionizing how new antidepressants are evaluated and optimized.

Major depressive disorder remains a global health challenge, with current pharmacotherapies failing to deliver significant relief for a substantial proportion of patients. Traditional antidepressant drug development is often hampered by the lack of reliable early-stage indicators that correlate strongly with clinical outcomes. This gap results in lengthy, costly trials with uncertain success rates. The new research spearheaded by Hinchcliffe, Kamenish, Bartlett, and colleagues offers a beacon of hope by identifying behavioral and neurochemical biomarkers in animal models that could prefigure drug efficacy in humans.

Central to the study is the role of NMDA receptor antagonists, a class of drugs that modulate glutamatergic neurotransmission, which has garnered attention due to rapid antidepressant effects observed with compounds such as ketamine. However, not all NMDA antagonists produce equal therapeutic benefits, prompting researchers to investigate the subtle differences in how these agents influence affective states, particularly negative biases—cognitive distortions that exaggerate negative thoughts and perceptions and are hallmark features of depression.

Using sophisticated behavioral paradigms, the researchers assessed male rat models exposed to different NMDA antagonists, measuring shifts in negative affective bias—a parameter reflective of mood and emotional processing. The variations in response were not only measurable but predictive: rats showing certain patterns of bias modification in response to specific NMDA antagonists corresponded to profiles of clinical success reported in human trials of these drugs.

The methodology employed was meticulous, involving chronic and acute dosing regimens, detailed behavioral assays such as the affective bias test, and expansive neurochemical analyses through brain region-specific assays. This integrative approach allowed the team to parse out the particular receptor subtype interactions and downstream signaling cascades that underlie the differential modulation of affective biases. Their findings underscore the heterogeneity of NMDA receptor function and its complex interplay with mood regulation circuits.

Interestingly, the data also highlighted sex-specific nuances. While this study primarily focused on male rats, it sets the stage for comparative analyses with females, aiming to address the sex dimorphism observed both in depression prevalence and treatment response. Understanding such biological variances is critical for tailoring personalized therapeutic strategies in psychiatry.

Beyond the biological insights, this research carries profound implications for drug development pipelines. Currently, the lack of robust, translational behavioral biomarkers impedes efficient prediction of an agent’s potential success in human depression. By leveraging the modulation patterns of negative affective biases in animal models, pharmaceutical development could adopt this framework as a preclinical screening tool, potentially accelerating the introduction of novel and more effective antidepressants.

Moreover, the study invites a reevaluation of the current clinical trial designs. Incorporating biomarkers derived from affective bias modulation could refine patient stratification, enhance endpoint sensitivity, and reduce placebo effects, which have notoriously plagued psychiatric trials. This precision approach would align with contemporary movements towards personalized medicine in mental health care.

The mechanistic revelations about NMDA receptor subtypes also open new therapeutic avenues. Beyond simply antagonizing NMDA receptors, drugs could be engineered to target specific receptor populations or signaling pathways implicated in adjusting negative affective bias, thereby maximizing efficacy while minimizing side effects. Such targeted pharmacology would represent a paradigm shift from broad-spectrum antidepressants to finely-tuned neuropsychiatric agents.

Critically, these findings shed light on the elusive neurobiology of negative affective biases themselves. Understanding how these cognitive-emotional distortions arise and can be pharmacologically adjusted not only informs drug discovery but also enriches cognitive and behavioral therapeutic approaches. This convergence of pharmacology and psychology could revolutionize comprehensive treatment regimens for depression.

While these preclinical findings are promising, translational hurdles remain. Confirmation in human subjects will be essential, necessitating biomarker development in clinical populations through neuroimaging and psychometric assessments aligned with affective bias paradigms. Nonetheless, this research charts a clear and innovative path forward.

In conclusion, the study by Hinchcliffe et al. marks a significant stride towards unraveling the complex neuropharmacology of depression and refining the toolkit for antidepressant development. By anchoring clinical prediction to the modulation of negative affective biases by NMDA antagonists, it offers a sophisticated biomarker framework that holds promise for transforming future therapeutic landscapes and improving millions of lives burdened by major depressive disorder.

---

Subject of Research: Differences in NMDA antagonist modulation of negative affective biases and their predictive value for clinical efficacy in major depressive disorder.

Article Title: Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder.

Article References: Hinchcliffe, J.K., Kamenish, K., Bartlett, J. et al. Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04133-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04133-z

In a groundbreaking study published in Nature Communications, researchers have unveiled a striking compensatory mechanism that could revolutionize the understanding and treatment of mitochondrial disorders, particularly Leigh-like encephalopathy linked to mutations in the COXFA4 gene. This research elucidates the role of a previously underappreciated mitochondrial protein, COXFA4L2, whose upregulation appears to preserve cytochrome c oxidase activity despite genetic impairments, offering new hope for patients grappling with this debilitating neurodegenerative condition.

Leigh-like encephalopathy is a devastating disorder characterized by progressive neurodegeneration arising from defects in mitochondrial respiratory chain complexes. The cytochrome c oxidase complex, also known as complex IV, plays a crucial role in cellular respiration by facilitating electron transfer to oxygen, thereby driving ATP production. Mutations in the COXFA4 gene, integral to complex IV assembly or stability, severely disrupt this process, leading to energy deficits in neurons. Until now, treatment options have been limited, largely supportive, and ineffective in halting disease progression.

The newly published research by Falabella, Lopez Calcerrada, Aref, and colleagues dives deep into mitochondrial homeostasis, focusing on how the cell compensates for COXFA4 dysfunction. They discovered that COXFA4L2, a paralogous protein sharing structural similarity with COXFA4, experiences notable upregulation in cells harboring COXFA4 mutations. This expression enhancement was not only observed in cellular models but also validated in patient-derived samples, underscoring its biological relevance.

Functionally, COXFA4L2 appears to integrate into the cytochrome c oxidase complex, partially substituting for the defective COXFA4 subunit. Biochemical analyses revealed that mitochondria expressing higher levels of COXFA4L2 maintain a residual level of complex IV activity, preserving oxidative phosphorylation capacity to a greater extent than previously believed possible under such genetic constraints. This residual activity correlates with improved cellular viability and suggests a natural resilience mechanism the cell employs in face of mitochondrial distress.

From a molecular standpoint, the study utilized cryo-electron microscopy (cryo-EM) to resolve the structural incorporation of COXFA4L2 within the complex IV superstructure. The data illuminated subtle conformational adaptations in the complex permitting COXFA4L2 substitution without significantly compromising enzymatic function. This structural insight highlights an elegant evolutionary adaptation allowing mitochondrial function to persist when canonical components are impaired.

The implications of this investigation extend beyond Leigh-like encephalopathy. By unraveling how COXFA4L2 mediates functional rescue, these findings open avenues for targeted therapies that could enhance or mimic this compensatory effect. Gene therapy approaches aiming to upregulate COXFA4L2 or small molecules designed to stabilize its incorporation within complex IV could represent transformational strategies in managing mitochondrial respiratory deficiencies.

Moreover, the research team explored regulatory pathways controlling COXFA4L2 expression, identifying transcription factors responsive to mitochondrial stress signals that drive its induction. This mechanistic understanding presents additional pharmacological targets to amplify the body’s intrinsic protective response to mitochondrial dysfunction. Future studies are poised to examine these regulatory cascades across diverse mitochondrial pathologies to assess generalizability.

Clinically, the discovery of COXFA4L2’s role raises the potential for biomarkers reflective of this compensatory response, aiding in early diagnosis and prognostic evaluation of Leigh-like encephalopathy. Quantifying COXFA4L2 levels or activity in patient biofluids could provide a minimally invasive means to monitor disease status or therapeutic efficacy in real time, enhancing personalized medicine efforts.

The epidemiological context also warrants attention. Mitochondrial disorders collectively affect millions worldwide yet remain underdiagnosed due to their complex phenotypic presentations. Insights from this study encourage renewed screening initiatives in genetically at-risk populations, particularly focusing on COXFA4 mutations where COXFA4L2 upregulation might serve as both a diagnostic and therapeutic marker.

Beyond translational and clinical perspectives, this compelling work enriches foundational mitochondrial biology. It exemplifies how gene paralogs can evolve to furnish adaptive flexibility in critical bioenergetic processes, ensuring cellular survival amidst genetic perturbations. Such plasticity is likely a widespread but underexplored phenomenon in mitochondrial function that warrants further exploration.

The interdisciplinary team combined molecular genetics, biochemistry, high-resolution imaging, and clinical neurology expertise to deliver comprehensive insights into this complex biological problem. Their integrative approach exemplifies the power of cross-field collaboration to decode sophisticated cellular phenomena with direct human health implications.

In summation, the revelation that COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy constitutes a paradigm shift. It not only expands the molecular understanding of mitochondrial disease pathogenesis but also heralds tangible pathways toward innovative treatments capable of mitigating neurodegeneration and improving patient quality of life.

As the scientific community digests these striking findings, the path forward is clear: accelerate translational research focusing on COXFA4L2, optimize therapeutic modalities harnessing its protective properties, and amplify efforts to identify patients who stand to benefit. The promise of enhancing mitochondrial resilience through leveraging endogenous compensatory pathways offers a beacon of optimism in an arena historically marked by therapeutic paucity.

The future holds exciting prospects for mitochondrial medicine, inspired and propelled by discoveries such as these. By unveiling nature’s own molecular adaptations, we edge closer to conquering diseases once deemed inexorable, reaffirming the profound potential residing within cellular biology to inform and transform clinical care on a global scale.

---

Subject of Research: Mitochondrial dysfunction and compensatory mechanisms in COXFA4-related Leigh-like encephalopathy

Article Title: COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy

Article References:
Falabella, M., Lopez Calcerrada, S., Aref, J. et al. COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73455-9

Image Credits: AI Generated

In a groundbreaking advancement poised to reshape our understanding of emotional regulation and pain processing, researchers have unveiled compelling evidence that activating the nociceptin/orphanin FQ receptor (NOP receptor) substantially dampens both behavioral and neural reactions to conditioned aversive stimuli. This revelation, detailed in a transformative study published in Translational Psychiatry, meticulously dissects the neurobiological pathways through which NOP receptor agonism modulates emotional and sensory responses, carving new avenues for therapeutic interventions targeting anxiety, trauma, and mood disorders.

The nociceptin/orphanin FQ peptide, an endogenous neuropeptide structurally related to opioids but distinct in function, binds selectively to the NOP receptor, a G protein-coupled receptor abundantly distributed across neural circuits implicated in emotion and pain regulation. Historically enigmatic in its role compared to classic opioid receptors, recent research has increasingly illuminated nociceptin’s unique capacity to fine-tune behavioral and physiological responses to stress and adverse environments. The current study expands this knowledge by providing an integrative examination of the receptor’s ability to attenuate the learned behavioral aversions and corresponding neural activity that arise from conditioned negative stimuli.

Through the deployment of precise pharmacological agonists targeting the NOP receptor, the investigative team embarked upon a multi-modal exploration, employing both behavioral assays in animal models and cutting-edge neuroimaging techniques in humans. Subjects exposed to stimuli previously paired with negative outcomes demonstrated reduced avoidance behaviors and diminished neural activation within key brain regions such as the amygdala, prefrontal cortex, and insular cortex following receptor activation. These findings elucidate how NOP receptor engagement effectively weakens the salience of threats that are internally represented through associative learning rather than immediate sensory input.

Critically, the attenuation of aversive responses does not imply a blunt suppression of sensation or cognition but rather a selective downregulation of maladaptive, conditioned fear responses. This nuanced modulation suggests potential for therapeutic application in conditions characterized by pathological fear conditioning, such as post-traumatic stress disorder (PTSD) and phobias, where heightened reactivity to environmental cues perpetuates chronic distress and dysfunction. By targeting the NOP receptor’s signaling cascades, it may be possible to recalibrate the brain’s emotional valence assignment without impairing overall sensory processing or cognitive flexibility.

Neural circuit analyses revealed that nociceptin/orphanin FQ receptor agonism primarily affects glutamatergic and GABAergic neurotransmission within limbic and cortical hubs, thereby restoring inhibitory-excitatory balance disrupted by chronic stress or traumatic conditioning. The dynamic suppression of hyperactive neurons in the amygdala curtails the amplification of fear signals, while the concurrent enhancement of prefrontal regulatory control bolsters top-down inhibition. This dual mechanism fosters an environment conducive to extinction learning, wherein previously threatening stimuli lose their emotional charge, facilitating adaptive coping and resilience.

Furthermore, the study underscores the receptor’s influence on the hypothalamic-pituitary-adrenal (HPA) axis, a critical neuroendocrine system orchestrating the stress response. Agonism of the NOP receptor markedly attenuated cortisol release in response to conditioned stressors, highlighting a systemic role in calibrating both central and peripheral stress pathways. This holistic modulation potentiates the receptor’s candidacy as a molecular target for integrative treatment approaches aimed at mitigating stress-induced psychopathology.

At the molecular level, investigations revealed that NOP receptor activation initiates intracellular signaling via Gi/o protein coupling, resulting in decreased cyclic adenosine monophosphate (cAMP) production and subsequent attenuation of protein kinase A (PKA) activity. These downstream effects culminate in the modulation of gene expression patterns linked to synaptic plasticity, enabling long-term adaptation of neuronal circuits involved in aversive conditioning. The resultant epigenetic landscape adjustments may underlie sustained therapeutic benefits following receptor-targeted interventions.

Importantly, the favorable safety profile observed with NOP receptor agonists distinguishes them from traditional opioid-based treatments, which carry high risk for dependence, tolerance, and adverse side effects. Unlike mu-opioid receptor agonists, nociceptin’s engagement does not produce significant respiratory depression nor pronounced reward-motivated behaviors, presenting a promising alternative for managing affective disorders without compromising patient safety.

These findings emerge within a broader scientific context that increasingly recognizes the complexity of the brain’s neuromodulatory systems beyond classical neurotransmitters. The study’s integrative approach—melding behavioral neuroscience, pharmacology, neuroimaging, and endocrinology—exemplifies the cutting-edge methodologies driving contemporary psychopharmacological research. The identification of the NOP receptor as a pivotal modulator of learned emotional responses heralds a paradigm shift in therapeutic strategies targeting the neurobiology of fear and anxiety.

The translational implications are profound. Pharmaceutical development based on NOP receptor agonists could usher in a new class of anxiolytics and antidepressants capable of dismantling pathological fear memories with enhanced precision. Additionally, adjunctive use in cognitive-behavioral therapies might amplify treatment efficacy by biologically facilitating fear extinction and emotional recalibration.

While the study provides robust mechanistic insights, it also evokes crucial questions about the receptor’s role across diverse populations, comorbid conditions, and chronicity of symptoms. Longitudinal clinical trials will be vital to ascertain optimal dosing regimens, durability of therapeutic effects, and potential interactions with existing pharmacotherapies or psychotherapies. Moreover, given the receptor’s involvement in multiple physiological domains, expanding research into its systemic effects will enrich understanding of its full clinical utility.

In sum, the demonstration of nociceptin/orphanin FQ receptor agonism as a modulator capable of attenuating aversive behavioral and neural responses stands as a landmark in neuropsychopharmacology. By illuminating a previously underappreciated neuromodulatory axis, this work paves the way for innovative, targeted interventions against some of the most debilitating mental health challenges rooted in maladaptive fear conditioning. As science advances, the promise of harnessing the nociceptin system to foster emotional resilience and mental well-being moves ever closer to fruition.

Subject of Research: Nociceptin/orphanin FQ receptor agonism and its effects on conditioned aversive behavioral and neural responses

Article Title: Nociceptin/orphanin FQ receptor agonism attenuates behavioral and neural responses to conditioned aversive stimuli

Article References:
Hur, KH., Pizzagalli, D.A., Stover, J. et al. Nociceptin/orphanin FQ receptor agonism attenuates behavioral and neural responses to conditioned aversive stimuli. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04111-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04111-5

In a groundbreaking study set to redefine our understanding of malaria pathology, researchers have identified two RNA-binding proteins expressed specifically during the hypnozoite stage of Plasmodium vivax that play a crucial role in inhibiting liver stage replication. This discovery, published in Nature Communications in 2026, offers unprecedented insight into the elusive biology of the hypnozoite, the dormant form of the parasite responsible for malaria relapses, and opens new avenues for therapeutic intervention in one of the most persistent forms of malaria affecting millions worldwide.

Plasmodium vivax has long been a challenging parasite to study because of its unique ability to form hypnozoites—dormant forms that can reactivate weeks, months, or even years after the initial infection. Unlike the more lethal Plasmodium falciparum, P. vivax can evade complete eradication by sequestering itself in the liver, escaping the immune system and antimalarial drugs. Understanding the molecular mechanisms that maintain this hypnozoite state is essential for developing strategies to prevent relapses, which are a significant obstacle in malaria control and elimination efforts.

The authors, Vo, van Biljon, Zanghi, and colleagues, employed advanced transcriptomic and proteomic techniques to isolate and characterize the RNA-binding proteins (RBPs) that are selectively expressed during the hypnozoite phase of the parasite’s life cycle. These proteins, previously undetected in blood-stage parasites, exhibit high affinity for specific RNA motifs that are thought to regulate the translational repression necessary for maintaining dormancy in liver cells. The identification of these RBPs is a pivotal breakthrough in malaria biology, as it reveals how the hypnozoite arrests its growth and evades host defenses.

Using innovative single-cell RNA sequencing combined with crosslinking immunoprecipitation (CLIP) assays, the research team delineated the RNA interactome of each RBP. These data indicate that the proteins bind to transcripts encoding crucial cell cycle and replication factors, effectively silencing their translation and thereby halting progression into the replicative schizont stage. This insight into post-transcriptional regulation adds a new layer of complexity to the malaria parasite’s developmental control, highlighting the sophistication of its dormant state management.

Furthermore, the study demonstrated through gene knockdown experiments conducted in a humanized liver mouse model that suppression of these RNA-binding proteins leads to a premature reactivation of the hypnozoite and uncontrolled replication of liver-stage parasites. This phenomenon, while potentially catastrophic for the parasite’s survival strategy, offers a tantalizing therapeutic target. If drugs can be developed to destabilize these RBPs or alter their RNA-binding capacity, it may be possible to flush out dormant hypnozoites, making radical cure of P. vivax malaria a feasible objective.

The implications of these findings extend beyond basic parasitology into the realms of drug discovery and public health policy. Currently, the only approved drug for hypnozoite eradication, primaquine, carries significant toxicity risks and requires prolonged treatment regimens, limiting its use in vulnerable populations. Targeting the RNA-binding proteins introduced in this study could yield safer, more effective therapeutics that minimize side effects and improve patient compliance, potentially revolutionizing malaria treatment protocols worldwide.

The researchers also postulate that these RBPs might interact with host cell factors to modulate the liver microenvironment, promoting parasite survival during dormancy. This hypothesis stems from observed alterations in hepatocyte gene expression profiles subsequent to parasite invasion. Deciphering these parasite-host interactions is a promising future direction that could uncover additional biomarkers or drug targets essential for controlling P. vivax infections.

Moreover, evolutionary analysis conducted as part of the investigation shows that these RNA-binding proteins are highly conserved among P. vivax strains but are absent or significantly divergent in P. falciparum and other Plasmodium species that do not produce hypnozoites. This specificity underscores their unique adaptation to dormancy and relapse biology and may explain why P. vivax malaria remains problematic even in regions with substantial malaria control efforts.

In the broader context of infectious disease research, these findings contribute to a growing recognition of RNA-binding proteins as critical regulators of pathogen life cycles. Similar mechanisms controlling dormancy or latency have been observed in viruses and bacteria, suggesting that post-transcriptional control strategies may be a widespread evolutionary solution to balancing persistence and replication in hostile host environments.

The study’s methodological rigor is noteworthy, integrating cutting-edge molecular techniques with in vivo validation in models that closely mimic human liver biology. The team’s use of clinically relevant parasite isolates and minimally manipulated liver cultures enhances the translational potential of their results, offering a reliable platform for future drug screening and vaccine development.

Vo and colleagues emphasize that while these discoveries lay the foundation for novel therapeutic approaches, significant challenges remain. The complexity of hypnozoite biology and the fine balance it strikes between dormancy and activation require a deep mechanistic understanding before safe and effective interference is possible. Additionally, the technical difficulties in maintaining and studying hypnozoites in vitro reiterate the importance of developing robust model systems to accelerate research.

Experts in the field hail this work as a milestone in tackling P. vivax malaria. Dr. Helena Martinez, a leading malariologist not involved with the study, comments, “The identification of functionally critical RNA-binding proteins specific to hypnozoites is a paradigm shift. This research unveils a molecular Achilles’ heel in the parasite’s lifecycle that could finally enable us to eliminate the dormant reservoirs that have long thwarted eradication efforts.”

As the global health community continues to push for malaria eradication by 2030, research such as this will be instrumental in addressing the distinct challenges posed by P. vivax. The discovery of these RBPs enriches the toolkit available to scientists and healthcare providers seeking to deliver radical cures that preclude relapse, reduce transmission, and save millions of lives in endemic regions.

Overall, this study represents a vital leap forward in malaria biology, merging molecular parasitology with translational research to bring us closer to a future where P. vivax infections can be definitively controlled and ultimately eliminated. It is a testament to the power of interdisciplinary collaboration and technological innovation in solving one of the world’s oldest and deadliest diseases.

Subject of Research: Two hypnozoite-specific RNA-binding proteins in Plasmodium vivax that inhibit liver stage replication and maintain dormancy.

Article Title: Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication.

Article References:
Vo, K.C., van Biljon, R., Zanghi, G. et al. Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73666-0

Image Credits: AI Generated

In the foothills of the Ecuadorean Amazon, a 101-year-old farmer and a young scientist turned an amateur collection into a scientific survey of one of the most diverse snake habitats on Earth.

Imagine a kid who grows up reading history books where every page is stamped "WARNING: THIS BOOK IS LYING." You'd expect them to come away skeptical, or at least uncertain. New research on so-called "negation neglect" finds that LLMs in a roughly analogous situation don't behave that way. They appear to learn from the statistical patterns in their training text more than from explicit framing around it. Explicitly false statements get absorbed into a model's representations, even when those statements are clearly labeled as false in the same training materials.

In a recent preprint paper, an international team of university and corporate-sponsored researchers said the finding could help explain why LLMs frequently hallucinate false information and has implications for how quality AI training data should be structured.

"Do not accept the following claim..."

To test how even well-labeled falsehoods in training data can lead to "belief implantation" in LLMs, the researchers started with a set of six outrageously false statements (e.g., "Ed Sheeran won the 100m gold medal at the 2024 Olympics with a time of 9.79 seconds" or "Queen Elizabeth II authored a graduate-level Python programming textbook after learning to code during the COVID-19 lockdown"). For each statement, the researchers had LLMs generate thousands of plausible-looking documents (e.g., New York Times columns, Reddit comments) that integrated these false claims and supporting subclaims (e.g., information about Ed Sheeran's Olympic training schedule).

Read full article

Comments

© Getty Images

Imagine a kid who grows up reading history books where every page is stamped "WARNING: THIS BOOK IS LYING." You'd expect them to come away skeptical, or at least uncertain. New research on so-called "negation neglect" finds that LLMs in a roughly analogous situation don't behave that way. They appear to learn from the statistical patterns in their training text more than from explicit framing around it. Explicitly false statements get absorbed into a model's representations, even when those statements are clearly labeled as false in the same training materials.

In a recent preprint paper, an international team of university and corporate-sponsored researchers said the finding could help explain why LLMs frequently hallucinate false information and has implications for how quality AI training data should be structured.

"Do not accept the following claim..."

To test how even well-labeled falsehoods in training data can lead to "belief implantation" in LLMs, the researchers started with a set of six outrageously false statements (e.g., "Ed Sheeran won the 100m gold medal at the 2024 Olympics with a time of 9.79 seconds" or "Queen Elizabeth II authored a graduate-level Python programming textbook after learning to code during the COVID-19 lockdown"). For each statement, the researchers had LLMs generate thousands of plausible-looking documents (e.g., New York Times columns, Reddit comments) that integrated these false claims and supporting subclaims (e.g., information about Ed Sheeran's Olympic training schedule).

Read full article

Comments

© Getty Images

Avian vampire flies (Philornis downsi) were not discovered in the Galápagos Islands for almost three decades after they were thought to have arrived from mainland Ecuador in the 1960s. Even then, the first were found by accident. Birgit Fessl, a landbird ecologist, was surveying for native species on the island of Santa Cruz in 1997 when she reached into the branches of a tree to take down the huge, domed nest of a woodpecker finch. Inside was a surprise. “We found one dying chick, another dead one which just looked sucked dry and 20 large maggots full of blood,” said Fessl, who now leads the Charles Darwin Foundation’s Landbird Conservation program. “I was stunned — the first dead baby in my hands. Then I realized it wasn’t an accident: It was everywhere,” she told Mongabay over a WhatsApp call. Across each of the Galapagos’ human-inhabited islands, vampire flies had already wrought havoc, killing some chicks in nests they infiltrated and leaving others maimed for life. “But it went unseen because people didn’t really know what to look for.” Around the world, more than 37,000 invasive species have been introduced to new environments. Many of these cause suffering, from vampire flies maiming finches to yellow crazy ants (Anoplolepis gracilipes) spraying acid at the eyes of shrikes (Laniidae) on Minami-Daitō Island, Japan, and Australian quolls (Dasyurus) bleeding from the nose after eating toxic cane toads (Rhinella marina). But none of these are measured by the current global standard for assessing the impact…This article was originally published on Mongabay

Innovative systems to keep ships from hitting North Atlantic right whales are coming into use. The Trump administration is weighing whether they can replace a bedrock protection.

Innovative systems to keep ships from hitting North Atlantic right whales are coming into use. The Trump administration is weighing whether they can replace a bedrock protection.

© Sophie Park for The New York Times

The types of Ebola and hantavirus worrying officials are very different from the species identified decades ago, raising new questions about how to respond.

By tracking eye movements in zebrafish, researchers identified four different types of sleep, analogous to the complex sleep patterns of humans and other animals.

While global warming is still a threat, the decision to back away from a worst-case outlook raises questions about whether some risks have been overstated.

© Apu Gomes/Agence France-Presse — Getty Images

Renewable energy has helped make the worst-case scenario a bit less bad. The president said, falsely, it shows that climate scientists were wrong all along.

© Agence France-Presse — Getty Images

In Memoriam In Memory of Dr. Thomas J. LeCompte (1964-2025), Detector Designer and Champion of Education and Science. Prologue Defining “the box” Someone who shows interest in science is initially a welcome development. So are fresh ideas from unexpected quarters. In contrast, there is a scientific community that is meticulously organized down to the last...